trial

Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

NCTId NCT01844726
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 44 (actual)
Sponsored by Northwestern University
Primary completion 2016-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
44 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2013-05
Primary completion
2016-01
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
GLYX-13

Sponsors

Northwestern UniversityLead Sponsor

Investigators

1
James L Reilly, PhDPrincipal Investigator

Sites

1 total
Chicago, United States

Linked catalysts

1
Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With — primary completion2016-01

Facts & assertions

4 sourced
Enrollment
44
Phase
PHASE2
Primary Completion Date
2016-01
Status
TERMINATED
relationships
The graph out of here
drug
GLYX-13
drug
lead_sponsor
Northwestern University
company
indication
Healthy
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
James L Reilly, PhD
person